K34c
| Code | Size | Price |
|---|
| TAR-T41151-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
K34c is a potent and selective α5β1 integrin inhibitor (IC50 = 3.1 nM). K34c inhibits cell survival and migration, inhibits p53-dependent senescence induced by Temozolomide or Ellipticine and promotes apoptosis in U87MG cells. K34c also prevents TGFβ-induced infiltrationin vivoand reduces cell adhesion on fibronectin.
CAS:
939769-93-4
Formula:
0
Molecular Weight:
0
Purity:
0.98
SMILES:
0
References
Kuonen et al (2018) TGF-?, fibronectin and integrin ?5?1 promote invasion in basal cell carcinoma. J.Invest.Dermatol. 138 2432 PMID: 29758283
Martinkova et al (2010) ?5?1 integrin antagonists reduce chemotherapy-induced premature senescence and facilitate apoptosis in human glioblastoma cells. Int.J.Cancer 127 1240 PMID: 20099278
Renner et al (2016) Expression/activation of ?5?1 integrin is linked to the ?-catenin signaling pathway to drive migration in glioma cells. Oncotarget 7 62194 PMID: 27613837
Heckmann et al (2007) Probing integrin selectivity: rational design of highly active and selective ligands for the ?5?1 and ?v?3 integrin receptor. Angew.Chem.Int.Ed.Engl 46 3571 PMID: 17394271